Item 2.02Results of Operations and Financial Condition.

On January 10, 2022, Orchard Therapeutics plc (the "Company") issued a press release announcing a preliminary unaudited estimate of its cash and investments as of December 31, 2021 (the "Financial Information"). A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K (the "Report"). The Financial Information is unaudited and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2021 and its results of operations for the three or twelve months ended December 31, 2021.

The Financial Information contained in Item 2.02 of this Report and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing

Item 7.01Regulation FD Disclosure.

The Company intends to participate in the 40th Annual J.P. Morgan Healthcare Conference during the week of January 10, 2022, including holding various investor and analyst meetings and presenting on January 13, 2022 at 9:00 a.m. Eastern time. A copy of the Company's presentation is attached as Exhibit 99.2 to this Report. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information contained in Item 7.01 of this Report and Exhibit 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.




Item 8.01Other Events.

On January 10, 2022, the Company issued a press release announcing its 2022 strategic priorities. A copy of the press release is attached as Exhibit 99.1 to this Report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
Number                                      Description
99.1        Press release, dated January 10, 2022
99.2        Presentation of Orchard Therapeutics plc
104       Cover page interactive data file (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses